SG11201501921SA - A method of purifying proteins - Google Patents

A method of purifying proteins

Info

Publication number
SG11201501921SA
SG11201501921SA SG11201501921SA SG11201501921SA SG11201501921SA SG 11201501921S A SG11201501921S A SG 11201501921SA SG 11201501921S A SG11201501921S A SG 11201501921SA SG 11201501921S A SG11201501921S A SG 11201501921SA SG 11201501921S A SG11201501921S A SG 11201501921SA
Authority
SG
Singapore
Prior art keywords
purifying proteins
purifying
proteins
Prior art date
Application number
SG11201501921SA
Other languages
English (en)
Inventor
Nathan Brinkman
Original Assignee
Csl Behring Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/803,525 external-priority patent/US9534029B2/en
Application filed by Csl Behring Llc filed Critical Csl Behring Llc
Publication of SG11201501921SA publication Critical patent/SG11201501921SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4717—Plasma globulins, lactoglobulin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201501921SA 2012-10-03 2013-10-01 A method of purifying proteins SG11201501921SA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261709342P 2012-10-03 2012-10-03
US13/803,525 US9534029B2 (en) 2012-10-03 2013-03-14 Method of purifying proteins
AU2013203930A AU2013203930B2 (en) 2012-10-03 2013-04-11 A method of purifying proteins
EP13170202 2013-06-03
PCT/US2013/062916 WO2014055552A1 (en) 2012-10-03 2013-10-01 A method of purifying proteins

Publications (1)

Publication Number Publication Date
SG11201501921SA true SG11201501921SA (en) 2015-04-29

Family

ID=52824845

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201501921SA SG11201501921SA (en) 2012-10-03 2013-10-01 A method of purifying proteins

Country Status (8)

Country Link
EP (1) EP2904005A1 (de)
JP (2) JP6370792B2 (de)
KR (2) KR102231613B1 (de)
CN (2) CN104968676A (de)
CA (2) CA2886726C (de)
HK (1) HK1212995A1 (de)
SG (1) SG11201501921SA (de)
WO (1) WO2014055552A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017025965A1 (en) 2015-08-13 2017-02-16 Kamada Ltd. Compositions derived from cohn fraction paste and use thereof
AU2017244763A1 (en) * 2016-03-29 2018-10-18 Kyowa Kirin Co., Ltd. Autoimmune disease therapeutic agent containing, as active ingredient, antibody that binds to haptoglobin in blood to form polyvalent immune complex
US12396943B2 (en) * 2017-08-08 2025-08-26 Csl Behring Ag Hemopexin formulations
ES2982322T3 (es) * 2018-04-18 2024-10-15 Sekisui Medical Co Ltd Método de análisis de hemoglobina
EP3968988A1 (de) 2019-05-17 2022-03-23 Universität Zürich Haptoglobin zur verwendung in der behandlung eines nachteiligen sekundären neurologischen ergebnisses nach einem hämorrhagischen schlaganfall
US11732004B2 (en) * 2020-04-10 2023-08-22 Plasma Technologies, Llc Compositions and methods for simplified high efficiency isolation of proteins
US20250339492A1 (en) 2021-02-01 2025-11-06 Csl Behring Ag Method of treating or preventing an adverse secondary neurological outcome following a haemorrhagic stroke
WO2022169206A1 (ko) * 2021-02-04 2022-08-11 ㈜Gc녹십자 헤모펙신 및 합토글로빈의 정제 방법
JP2026502812A (ja) 2022-12-22 2026-01-27 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 混合モードクロマトグラフィーを使用するヘモペキシンの精製方法
CN116179636A (zh) * 2023-01-12 2023-05-30 合肥工业大学 一种血红素和珠蛋白的联产制备方法
WO2025168750A1 (en) 2024-02-09 2025-08-14 Csl Behring Ag Haptoglobin for use in treating traumatic brain injury (tbi)
WO2025257801A1 (en) 2024-06-13 2025-12-18 CSL Innovation Pty Ltd Heme-binding protein for the treatment of ischemia-reperfusion injury (iri)

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1426039A (en) * 1973-11-15 1976-02-25 Green Cross Corp Haptoglobin in aqueous solution and process for tits preparation
JPS5337406B2 (de) * 1973-11-15 1978-10-09
US4129648A (en) * 1977-11-21 1978-12-12 Collier Harry O J Method for reducing endogenous prostaglandin synthesis
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US4764369A (en) 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
JPS6317899A (ja) * 1986-07-09 1988-01-25 Green Cross Corp:The ハプトグロビンの精製方法
JPH01305036A (ja) * 1988-05-31 1989-12-08 Green Cross Corp:The 血漿蛋白成分の加熱処理方法および血漿蛋白成分製剤
US5169936A (en) * 1989-04-14 1992-12-08 Biogen, Inc. Protein purification on immobilized metal affinity resins effected by elution using a weak ligand
US5138034A (en) * 1989-07-12 1992-08-11 The Green Cross Corporation Method of fractionating plasma proteins
FR2672604B1 (fr) * 1991-02-07 1995-05-05 Pasteur Merieux Serums Vacc Procede pour isoler de l'albumine humaine a partir du surnageant iv, notamment iv-4, ou de la fraction v de cohn ou d'un surnageant ou fraction analogue.
SE9301582D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Purification of plasma proteins
DE19830914C1 (de) * 1998-07-10 1999-06-24 Centeon Pharma Gmbh Verfahren zur Herstellung einer Proteinlösung
US6093804A (en) * 1998-09-24 2000-07-25 American National Red Cross Method for purification of alpha-1 proteinase inhibitor
US6815181B2 (en) * 2001-07-09 2004-11-09 Applera Corporation Nucleic acid molecules encoding human secreted hemopexin-related proteins
DE10211632A1 (de) 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
DE10215315A1 (de) * 2002-04-05 2003-11-20 Aventis Behring Gmbh Intellect Human-Transferrin zur Behandlung der Anaemia of Chronic Disease (ACD) und des funktionellen Eisenmangels
AU2002307776A1 (en) * 2002-04-16 2003-10-27 Kamada Ltd. Ultrapure transferrin for pharmaceutical compositions
DE10261126A1 (de) 2002-08-13 2004-03-04 Aventis Behring Gmbh Lagerungsstabile, flüssige Fibrinogen-Formulierung
JP2004224793A (ja) * 2003-01-17 2004-08-12 Research Corp Technologies Inc 子宮内膜症の治療方法
JP2004256463A (ja) * 2003-02-26 2004-09-16 Univ Waseda 多形核白血球の細胞接着抑制剤及び細胞接着抑制方法
GB0423196D0 (en) * 2004-10-19 2004-11-24 Nat Blood Authority Method
US7291338B2 (en) * 2005-03-09 2007-11-06 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
EP2059818A2 (de) * 2006-05-15 2009-05-20 Digilab, Inc. Biomarker für die vorform von typ 2 diabetes und verfahren zum nachweis der an- oder abwesenheit einer vorform von typ 2 diabetes
WO2009025754A2 (en) * 2007-08-17 2009-02-26 Csl Behring Gmbh Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i
EP2027875A1 (de) * 2007-08-23 2009-02-25 Octapharma AG Verfahren zur Isolierung und Reinigung eines prionenproteinfreien Target-Proteins
KR101426039B1 (ko) * 2008-09-11 2014-08-01 삼성테크윈 주식회사 얼굴/물체 인식을 위한 특징점 검출 장치 및 방법
FR2942233B1 (fr) * 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
EP2236617A1 (de) * 2009-03-31 2010-10-06 Leukocare Ag Verfahren zur Endsterilisierung von biofunktionalen Zusammensetzungen
WO2011002070A1 (ja) * 2009-07-02 2011-01-06 協和発酵キリン株式会社 Ｇｄｆ７／ｂｍｐ１２蛋白質を含有する鉄過剰疾患または鉄濃度を低下させることが有効な疾患に対する治療用医薬組成物
EP2453892B1 (de) * 2009-07-16 2013-05-29 Institut National de la Santé et de la Recherche Medicale Pharmazeutische zusammensetzungen und deren verwendung zur krebstherapie
ES2360782B1 (es) * 2009-07-28 2012-03-12 Grifols, S.A. Medios para cultivo de células de mamíferos que comprenden sobrenadante de etapas del fraccionamiento de Cohn y uso de los mismos.
PL2464655T3 (pl) * 2009-08-11 2017-08-31 Biocon Limited Procesy chromatograficzne
CN103003422B (zh) * 2010-04-20 2015-02-11 奥克塔法马股份有限公司 用于药物蛋白的新型稳定剂
WO2012050874A2 (en) * 2010-09-28 2012-04-19 Soares Miguel P Targeting heme for the treatment of immune mediated inflammatory diseases

Also Published As

Publication number Publication date
JP6876655B2 (ja) 2021-05-26
EP2904005A1 (de) 2015-08-12
CA3129057C (en) 2023-03-07
JP2015532301A (ja) 2015-11-09
KR20150063547A (ko) 2015-06-09
CN104968676A (zh) 2015-10-07
WO2014055552A1 (en) 2014-04-10
JP6370792B2 (ja) 2018-08-08
CA2886726A1 (en) 2014-04-10
JP2018172426A (ja) 2018-11-08
CN112717125A (zh) 2021-04-30
HK1212995A1 (zh) 2016-06-24
KR102125695B1 (ko) 2020-06-24
CA2886726C (en) 2021-11-23
KR102231613B1 (ko) 2021-03-25
CA3129057A1 (en) 2014-04-10
KR20200075027A (ko) 2020-06-25

Similar Documents

Publication Publication Date Title
SG11201504372UA (en) A method of purifying therapeutic proteins
GB201217772D0 (en) Sequencing method
PT2768857T (pt) Métodos para purificar anticorpos
IL232558B (en) A method for antibody purification
ZA201305971B (en) Method for the purification of biphephos
PT2791176T (pt) Um método de purificação de anticorpos
IL239556A0 (en) Human anti-tau antibodies
IL228438A0 (en) New methods for protein purification
IL227593A (en) A method for making noribogain from Wakanjin and purifying it
SG11201405296QA (en) Method for purifying acetonitrile
IL228913A0 (en) A method for cleaning Mitzfungin
HUE043121T2 (hu) Eljárás antitest tisztítására
GB201222693D0 (en) Novel method
SG10201606218WA (en) Purified Proteins
IL268868B (en) A new method for protein purification
SG11201501216XA (en) Method for purifying acetonitrile
GB201209082D0 (en) Purification method
PL3202769T3 (pl) Sposoby oczyszczania związków fosfaplatyny
SG2013017017A (en) A method of separation
EP2743259A4 (de) Verfahren zur reinigung von (s) -oxiracetam
GB201220155D0 (en) Method of manufacture
EP2743258A4 (de) Verfahren zur aufreinigung levo-oxiracetam
PL2934172T3 (pl) Sposób oczyszczania lecytyny
GB201215942D0 (en) Method of treatent
SI2844076T1 (sl) Postopek pridobivanja rastlinskih proteinov